Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
As part of the collaboration,the
Novavax announced plans to develop a Covid-19 vaccine candidate in January and begin testing its candidates in animal models in February.
Previously, the company developed MERS and SARS vaccines, said to have shown encouraging immunogenicity and complete protection in preclinical testing.
Last month, Novavax acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, currently in a Phase IIb clinical trial.